title: Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?
abstract: Mantle cell lymphoma is a relatively rare subtype of lymphoma with a great deal of heterogeneity, both clinically and biologically. Since its recognition as a separate entity in the early 1990s though, consistent efforts have led to a significant improvement of overall survival, from a median overall survival of 2.5 years initially to 5-7 years currently. This decades-long and stepwise progress, summarized in the article, definitely accelerated recently, shedding light on a changing paradigm.
authors.affiliation: John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA. Electronic address: agoy@hackensackUMC.org.
authors.forename: Andre
authors.initials: A
authors.lastname: Goy
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000401:mortality* / Q000628:therapy*; D015996:Survival Rate
keywords: Bortezomib; Ibrutinib; Lenalidomide; MRD; Maintenance; Mantle cell; Novel therapies; Stem cell transplantation